Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial

[1]  J. Witjes,et al.  Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer , 2021, Prostate cancer and prostatic diseases.

[2]  Steffie M. B. Peters,et al.  Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  T. Scheenen,et al.  Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients , 2021, The Journal of Nuclear Medicine.

[4]  Henk G van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.

[5]  J. Witjes,et al.  Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology , 2020, Prostate Cancer and Prostatic Diseases.

[6]  H. G. van der Poel,et al.  Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial , 2020, BMC cancer.

[7]  Sean S. Park,et al.  Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer , 2020, International journal of radiation oncology, biology, physics.

[8]  G. Ploussard.  Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. , 2020, European urology.

[9]  Steffie M. B. Peters,et al.  Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study , 2020, Clinical Cancer Research.

[10]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[11]  E. Goetghebeur,et al.  Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. , 2020 .

[12]  T. Derlin,et al.  Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  D. Murphy,et al.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes , 2018, The Journal of Nuclear Medicine.

[14]  L. Collette,et al.  Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. , 2018, The Lancet. Oncology.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Publisher's Note , 2018, Anaesthesia.

[18]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[19]  K. Pienta,et al.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.

[20]  S. Daneshmand,et al.  Androgen deprivation therapy: evidence‐based management of side effects , 2013, BJU international.

[21]  J. Eastham,et al.  Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer , 2009, Prostate Cancer and Prostatic Diseases.

[22]  A. D'Amico,et al.  Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.